211 related articles for article (PubMed ID: 8895732)
1. Somatic mutations of the RET proto-oncogene are not required for tumor development in multiple endocrine neoplasia type 2 (MEN 2) gene carriers.
Landsvater RM; de Wit MJ; Zewald RA; Hofstra RM; Buys CH; Ploos van Amstel HK; Höppener JW; Lips CJ
Cancer Res; 1996 Nov; 56(21):4853-5. PubMed ID: 8895732
[TBL] [Abstract][Full Text] [Related]
2. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
3. Germ line mutations of the ret proto-oncogene in Japanese patients with multiple endocrine neoplasia type 2A and type 2B.
Maruyama S; Iwashita T; Imai T; Funahashi H; Ceccherini I; Luo Y; Romeo G; Matsuo S; Matsuyama M; Takahashi M
Jpn J Cancer Res; 1994 Sep; 85(9):879-82. PubMed ID: 7961113
[TBL] [Abstract][Full Text] [Related]
4. High prevalence of the C634Y mutation in the RET proto-oncogene in MEN 2A families in Spain.
Sánchez B; Robledo M; Biarnes J; Sáez ME; Volpini V; Benítez J; Navarro E; Ruiz A; Antiñolo G; Borrego S
J Med Genet; 1999 Jan; 36(1):68-70. PubMed ID: 9950371
[TBL] [Abstract][Full Text] [Related]
5. The RET protooncogene in sporadic pheochromocytomas: frequent MEN 2-like mutations and new molecular defects.
Beldjord C; Desclaux-Arramond F; Raffin-Sanson M; Corvol JC; De Keyzer Y; Luton JP; Plouin PF; Bertagna X
J Clin Endocrinol Metab; 1995 Jul; 80(7):2063-8. PubMed ID: 7608256
[TBL] [Abstract][Full Text] [Related]
6. Identification of multiple endocrine neoplasia, type 2 gene carriers using linkage analysis and analysis of the RET proto-oncogene.
Tsai MS; Ledger GA; Khosla S; Gharib H; Thibodeau SN
J Clin Endocrinol Metab; 1994 May; 78(5):1261-4. PubMed ID: 7909818
[TBL] [Abstract][Full Text] [Related]
7. Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2.
Pausova Z; Soliman E; Amizuka N; Janicic N; Konrad EM; Arnold A; Goltzman D; Hendy GN
J Clin Endocrinol Metab; 1996 Jul; 81(7):2711-8. PubMed ID: 8675600
[TBL] [Abstract][Full Text] [Related]
8. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
Chiefari E; Russo D; Giuffrida D; Zampa GA; Meringolo D; Arturi F; Chiodini I; Bianchi D; Attard M; Trischitta V; Bruno R; Giannasio P; Pontecorvi A; Filetti S
J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127
[TBL] [Abstract][Full Text] [Related]
9. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s.
Zedenius J; Wallin G; Hamberger B; Nordenskjöld M; Weber G; Larsson C
Hum Mol Genet; 1994 Aug; 3(8):1259-62. PubMed ID: 7987299
[TBL] [Abstract][Full Text] [Related]
10. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
Sansó G; Domené HM; Iorcansky S; Barontini M
Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252
[TBL] [Abstract][Full Text] [Related]
11. Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations.
Rossel M; Pasini A; Chappuis S; Geneste O; Fournier L; Schuffenecker I; Takahashi M; van Grunsven LA; Urdiales JL; Rudkin BB; Lenoir GM; Billaud M
Oncogene; 1997 Jan; 14(3):265-75. PubMed ID: 9018112
[TBL] [Abstract][Full Text] [Related]
12. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes and Hirschsprung disease.
Smith DP; Eng C; Ponder BA
J Cell Sci Suppl; 1994; 18():43-9. PubMed ID: 7883791
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.
Kambouris M; Jackson CE; Feldman GL
Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338
[TBL] [Abstract][Full Text] [Related]
14. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation.
Kawai K; Iwashita T; Murakami H; Hiraiwa N; Yoshiki A; Kusakabe M; Ono K; Iida K; Nakayama A; Takahashi M
Cancer Res; 2000 Sep; 60(18):5254-60. PubMed ID: 11016655
[TBL] [Abstract][Full Text] [Related]
15. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
Marsh DJ; Mulligan LM; Eng C
Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
[TBL] [Abstract][Full Text] [Related]
16. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2.
Ponder BA
Cancer Surv; 1995; 25():195-205. PubMed ID: 8718519
[No Abstract] [Full Text] [Related]
17. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B.
Santoro M; Carlomagno F; Romano A; Bottaro DP; Dathan NA; Grieco M; Fusco A; Vecchio G; Matoskova B; Kraus MH
Science; 1995 Jan; 267(5196):381-3. PubMed ID: 7824936
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and management of pheochromocytomas in patients with multiple endocrine neoplasia type 2-relevance of specific mutations in the RET proto-oncogene.
Frank-Raue K; Kratt T; Höppner W; Buhr H; Ziegler R; Raue F
Eur J Endocrinol; 1996 Aug; 135(2):222-5. PubMed ID: 8810737
[TBL] [Abstract][Full Text] [Related]
19. RET proto-oncogene mutations in French MEN 2A and FMTC families.
Schuffenecker I; Billaud M; Calender A; Chambe B; Ginet N; Calmettes C; Modigliani E; Lenoir GM
Hum Mol Genet; 1994 Nov; 3(11):1939-43. PubMed ID: 7874109
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.
Donis-Keller H; Dou S; Chi D; Carlson KM; Toshima K; Lairmore TC; Howe JR; Moley JF; Goodfellow P; Wells SA
Hum Mol Genet; 1993 Jul; 2(7):851-6. PubMed ID: 8103403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]